Overview

ZAP, US. Zomig for Appropriate for Primary Care

Status:
Completed

Trial end date:
2005-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine how useful and effective the use of ZOMIG-ZMT™ (zolmitriptan) 5.0 mg and ZOMIG® Nasal Spray (zolmitriptan) 5.0 mg is for patients, in treating migraine over a period of 6 months

Phase:

Phase 4

Details

Lead Sponsor:

AstraZeneca

Treatments:

Oxazolidinones
Zolmitriptan